New Landmark Study Documents Long-Term Safety, Efficacy of Cognis' Tonalin CLA

Results of First Long-term CLA Study Published in American Journal of Clinical Nutrition Show Tonalin(R) Helps Reduce Body Fat By as Much as Nine Percent

The first study to document the long-term safety and efficacy of TONALIN® conjugated linoleic acid (CLA) supplementation will be published in the June issue of The American Journal of Clinical Nutrition (Gaullier J-M. et al., "Conjugated linoleic acid (CLA) supplementation for one-year reduces body fat mass in healthy, overweight humans". American Journal of Clinical Nutrition, 2004; 79(6):1118-1125). Researchers found that TONALIN® CLA, an exclusive product of the Cognis Group, reduces body fat mass in overweight, but otherwise healthy, adults by as much as nine percent. The randomized, double blind, placebo-controlled study was conducted over a 12-month period without additional lifestyle or dietary restrictions.

This long-term clinical trial supports earlier research that found TONALIN® CLA improves body composition by reducing fat and preserving lean muscle tissue.

"The results of this first long-term study indicate that CLA, taken for one year as a dietary supplement, safely improves the ratio of body fat to lean tissue in overweight, but otherwise healthy, adults," said Dr. Jean-Michel Gaullier, of Scandinavian Clinical Research in Kjeller, Norway, and project manager of the study. "Study participants who took 3.4 grams of CLA per day experienced a significant reduction in their body fat mass compared to those in the placebo group. These results confirm a trend observed in previous short-term CLA studies."

Nina Likins, TONALIN® Marketing Manager, Cognis Nutrition & Health, explained that this “landmark study is an important milestone in TONALIN® history. The majority of all published, clinical research on CLA has been done with TONALIN® CLA, and now with Dr. Gaullier’s findings, we have compelling scientific evidence that will continue to make TONALIN® the #1 consumer brand of CLA sold worldwide.” Seven clinical studies published within the last four years, in peer-reviewed journals, all indicate significant improvement in at least one body composition measurement with TONALIN® CLA. “This news translates into valuable marketing opportunities for our customers. We will be supporting their efforts through a global public relations program that communicates this research news to targeted audiences,” Ms. Likins said. Included in the PR program is a Video News Release (VNR) in English and in Spanish to be aired on television stations throughout North America.

TONALIN® CLA has been clinically proven to aid in the maintenance of lean tissue and may help tone the body without necessarily causing overall weight loss. It is thought to do this by decreasing the amount of fat stored after eating, increasing the rate of fat breakdown and metabolism—helping the body use its existing fat for energy—and decreasing the total number of fat cells.

In the study, 180 healthy men and women volunteers, ages 18 to 65, with a body mass index (BMI) of 25-30 kg/m2 (indicating that they were overweight) were randomized to receive soft gel capsules containing either 3.4 grams CLA-free fatty acid, 3.4 grams CLA-triglycerides or equivalent amounts of olive oil (placebo). Patients were then followed for 12 months. Weight, BMI, vital signs and adverse events were recorded every three months. Body composition and blood samples were analyzed at regular intervals throughout the study, and participants were monitored continuously for any signs of serious adverse events. At baseline, there was no difference between the groups for either weight, BMI, body fat mass or lean body mass. After only six months of observation, individuals taking either form of CLA experienced a significant reduction in body fat mass, while those in the placebo group saw no change.

Daily caloric intake and exercise was not different between groups either at zero or 12 months and thus most likely did not play a role in body composition changes observed in the CLA groups. Both forms of CLA were equally efficacious in body fat mass reduction and proven safe, when used for one year in healthy, yet overweight adults. Study related adverse events, typically rated as “mild” or “moderate” in nature, were nearly equal among groups taking either CLA or placebo (3-5 percent). The most common side effect was gastrointestinal complaints.

Based on the findings of this study, researchers concluded that TONALIN® CLA “administered either in the triglyceride or free fatty acid form, in healthy, overweight adults for one year, results in a significant decrease of body fat mass (BFM).”

Nina Likins,Marketing Manager for TONALIN®
Cognis Nutrition and Health
Email Address: [email protected]
Telephone: 708/579-6197

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.